Protagonist Therapeutics Inc (PTGX)
20.73
-0.28
(-1.33%)
USD |
NASDAQ |
Mar 24, 16:00
20.72
0.00 (0.00%)
After-Hours: 20:00
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 1.063B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -17.64% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 22.35 |
| Price to Book Value | 4.930 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 85.79% |
News
Headline
Wire
Time (ET)
Yahoo
03/21 03:49
Yahoo
03/20 06:08
Yahoo
03/17 06:06
MT Newswires
03/16 09:32
HC Wainwright Adjusts Price Target on Protagonist Therapeutics to $38 From $33, Maintains Buy Rating
MT Newswires
03/16 09:30
Yahoo
03/15 16:01
MT Newswires
03/15 10:01
Accesswire
03/15 07:30
SA Breaking News
03/10 21:26
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 05/04/2023* | -- | Results | Q1 2023 | -- | -0.70 | -- | |
| 03/15/2023 | -- | Results | Q4 2022 | -0.69 | -0.61 | -12.97% | |
| 11/08/2022 | -- | Results | Q3 2022 | -0.64 | -0.82 | 22.25% | |
| 08/04/2022 | -- | Results | Q2 2022 | -0.84 | -0.98 | 14.30% | |
| 05/04/2022 | -- | Results | Q1 2022 | -0.43 | -0.60 | 27.94% | |
| 02/28/2022 | -- | Results | Q4 2021 | -0.77 | -0.76 | -1.23% | |
| 11/03/2021 | -- | Results | Q3 2021 | -0.70 | -0.66 | -5.74% | |
| 08/04/2021 | -- | Results | Q2 2021 | -0.69 | -0.53 | -30.25% |
*Estimated Date/Time
Earnings
Profile
Edit
| Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113. |
| URL | https://www.protagonist-inc.com |
| Investor Relations URL | https://www.protagonist-inc.com/events-presentations |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | May. 04, 2023 (est.) |
| Last Earnings Release | Mar. 15, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0.00% |
| Forward Yield | -- |
| Payout Ratio | -- |
| Cash Payout Ratio | -- |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk
Total Returns Comparison
Annual Total Returns Versus Peers
As of March 24, 2023.
Fundamentals
| Revenue (TTM) | -- |
| Total Expenses (TTM) | 157.95M |
| Net Income (TTM) | -127.39M |
| Total Assets (Quarterly) | 247.93M |
| Total Liabilities (Quarterly) | 32.32M |
| Shareholders Equity (Quarterly) | 215.61M |
| Cash from Operations (TTM) | -108.14M |
| Cash from Investing (TTM) | 91.47M |
| Cash from Financing (TTM) | 18.84M |
Ratings
Profile
Edit
| Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113. |
| URL | https://www.protagonist-inc.com |
| Investor Relations URL | https://www.protagonist-inc.com/events-presentations |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | May. 04, 2023 (est.) |
| Last Earnings Release | Mar. 15, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| PTGX Tweets |